QSI

QuantumSi Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$182.62M
P/E Ratio
—
EPS
$-0.45
Beta
3.25
52W High
$3.10
52W Low
$0.69
50-Day MA
$0.77
200-Day MA
$0.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About QuantumSi Inc

Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.60M
Gross Profit (TTM)562,000
EBITDA$-87.36M
Operating Margin-7450.00%
Return on Equity-49.10%
Return on Assets-25.70%
Revenue/Share (TTM)$0.01
Book Value$0.82
Price-to-Book0.92
Price-to-Sales (TTM)113.78
EV/Revenue36.04
EV/EBITDA0.63
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-41.80%
Shares Outstanding$198.95M
Float$192.10M
% Insiders10.45%
% Institutions24.82%

Historical Volatility

HV 10-Day
54.85%
HV 20-Day
43.00%
HV 30-Day
64.45%
HV 60-Day
61.67%
HV Rank
14.3%

Volatility is currently contracting

Latest News

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments.

GlobeNewsWire9/15/2026Neutral
Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing.

GlobeNewsWire9/9/2026Neutral
Quantum-Si Q2 Earnings Call Highlights

Quantum-Si NASDAQ: QSI said it has moved the planned launch of its Proteus protein sequencing platform to the second quarter of 2027 from the end of 2026, citing the need for an additional integrated instrument design cycle before production. The company also announced a targeted workforce reduction of about 20% as it seeks to lower cash burn and fund the revised development timeline.

MarketBeat8/14/2026Neutral
Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update

Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new market opportunities for protein sequencing BRANFORD, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced financial results for the second quarter ended June 30, 2026.

GlobeNewsWire8/13/2026Neutral
Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026

BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the second quarter 2026 on Thursday, August 13, 2026.

GlobeNewsWire7/27/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QSI and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026